All In Biotech

Drug Trial Radar · NCT05131477

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

390

Actual

Start

Dec 13, 2021

Primary completion

Apr 26, 2023

Study completion Feb 21, 2024

Sponsor

Lead sponsor
Kymab LimitedIndustry
Sponsor type
Industry
Collaborators
Sanofi
First posted
Nov 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 28 days for screening and then up to approximately day 477 (last dose no later than day 337+140 days safety follow-up) for all patients unless enrolled into the Long-Term Extension (LTE) protocol (NCT05492578) at either Day 169 depending on responder status or no later than Day 365 due to loss of clinical response.

Conditions

  • Eczema
  • Atopic Dermatitis

Interventions

  • AmlitelimabDrug

    Pharmaceutical form: Injection solution Route of administration: Subcutaneous

  • PlaceboDrug

    Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1)Time frame: Baseline to week 16

Locations

103 sites in 12 countries. Site status is shown where the registry gives one.

  • Investigative Site Number: 1018

    Fremont, California

  • Investigative site #1022

    Sacramento, California

  • Investigative Site Number: 1006

    Boca Raton, Florida

  • Investigative Site Number: 1001

    Clearwater, Florida

  • Investigative Site Number: 1019

    Coral Gables, Florida

  • Investigative Site Number: 1007

    Miami, Florida

  • Investigative Site Number: 1013

    Tampa, Florida

  • Investigative Site Number: 1004

    Savannah, Georgia

  • Investigative Site Number: 1010

    Clarksville, Indiana

  • Investigative Site Number: 1015

    Indianapolis, Indiana

  • Investigative Site Number: 1021

    Louisville, Kentucky

  • Investigative Site Number: 1011

    Towson, Maryland

  • Investigative Site Number: 1014

    Beverly, Massachusetts

  • Investigative Site Number: 1012

    Troy, Michigan

  • Investigative Site Number: 1005

    Tulsa, Oklahoma

  • Investigative Site Number: 1017

    Portland, Oregon

  • Investigative Site Number: 1009

    Portland, Oregon

  • Investigative Site Number: 1003

    Anderson, South Carolina

  • Investigative Site Number: 1008

    Murfreesboro, Tennessee

  • Investigative site #1023

    Mansfield, Texas

  • Investigative Site Number 3002

    Carlton, Australia

  • Investigative Site Number: 3003

    East Melbourne, Australia

  • Investigational Site Number: 3001

    Parkville, Australia

  • Investigative Site Number: 2004

    Pleven, Bulgaria

  • Investigative Site Number: 2005

    Sofia, Bulgaria

  • Investigative Site Number: 2006

    Sofia, Bulgaria

  • Investigative Site Number: 2003

    Sofia, Bulgaria

  • Investigative Site Number: 2002

    Sofia, Bulgaria

  • Investigative Site Number: 2001

    Stara Zagora, Bulgaria

  • Investigative Site Number: 1106

    Markham, Ontario, Canada

  • Investigative site #1108

    Niagara Falls, Ontario, Canada

  • Investigative Site Number: 1103

    Ottawa, Ontario, Canada

  • Investigative Site Number: 1107

    Waterloo, Ontario, Canada

  • Investigative Site Number: 1101

    Windsor, Ontario, Canada

  • Investigative Site Number: 2106

    Kutná Hora, Czechia

  • Investigative Site Number: 2104

    Ostrava, Czechia

  • Investigative Site Number: 2105

    Nový Jicín, Moravian-Silesian Region, Czechia

  • Investigative Site Number: 2102

    Prague, Praha, Hlavní Mesto, Czechia

  • Investigative Site Number: 2103

    Prague, Praha, Hlavní Mesto, Czechia

  • Investigative Site Number: 2108

    Brno, South Moravian, Czechia

Showing 40 of 103 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.